# Shikonin in Oncology Shikonin is a naturally occurring naphthoquinone pigment extracted from the roots of *Lithospermum erythrorhizon*. In oncology research, it stands out for **PKM2 inhibition**, **dual cell-death signalling**, and **multi-level estrogen-receptor disruption**. It also matters in the wider metabolic-pressure conversation because it targets a glycolytic isoform that cancer cells use far more than most healthy adult tissues. {% hint style="warning" %} This content is educational only. Shikonin should not replace standard cancer treatment. Because it may affect estrogen signalling, treatment sensitivity, liver stress, and drug handling, use should be discussed with a clinician and pharmacist, especially during chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. {% endhint %} ### At a glance * **What it is:** A natural naphthoquinone from *Lithospermum erythrorhizon* root * **Why it matters:** Repeatedly inhibits PKM2, disrupts aerobic glycolysis, and can drive both apoptosis and necroptosis * **What makes it unusual:** It can kill apoptosis-resistant tumour cells through RIPK1/RIPK3-linked necroptosis * **Best-supported use today:** Investigational only, with strongest current preclinical depth in breast and bladder cancer * **Strongest current discussion areas:** PKM2 and the Warburg effect, ER-pathway disruption, resistance sensitisation, and ferroptosis in thyroid cancer * **Main limitation:** There are no clinical oncology trials showing anticancer outcomes in humans ### Why shikonin gets attention in oncology Three mechanisms drive most of the interest. #### PKM2 inhibition Pyruvate kinase M2 is the glycolytic isoform favoured by tumour cells. It supports the Warburg effect and helps route glucose into biomass production rather than efficient energy extraction. Shikonin is one of the best-known natural PKM2 inhibitors. Across breast, bladder, liver, oesophageal, and pancreatic models, it reduces glycolytic flux, lowers lactate output, and creates metabolic stress inside tumour cells. #### Dual cell-death induction Most anticancer compounds lean mainly on apoptosis. Shikonin does not stop there. It can also trigger necroptosis through the RIPK1-RIPK3 axis. That matters because many resistant tumour cells have already learned to block apoptosis through Bcl-2 overexpression, caspase dysfunction, or p53-related escape. In selected settings, shikonin has also been linked to ferroptosis. #### Estrogen-receptor degradation In ER-positive settings, shikonin promotes ERα protein degradation via the proteasome, suppresses ERα-driven transcriptional activity, downregulates GPER membrane signalling, and may inhibit steroid sulfatase — the enzyme that generates active oestrogen locally within tumour tissue. That combination gives shikonin a more specific and mechanistically grounded place in hormone-driven oncology discussions than most broad-spectrum phytochemicals can claim. ### The distinctive angle The most clinically interesting part of the shikonin story is not just that it kills cancer cells. It is that it can kill cells that have already become hard to kill. Necroptosis gives shikonin a route around classic apoptosis resistance. That is why the bladder-cancer and resistant-breast-cancer work keeps drawing attention. ### Clinical positioning Current evidence supports shikonin as an investigational compound with strong mechanistic interest and no established treatment role. The most reasonable use of the literature today is to track where it may matter next. That means: * mechanism-based interest in ER-positive breast cancer and other hormone-sensitive settings * resistance and sensitisation interest in cisplatin-resistant bladder cancer * broader metabolic interest in PKM2-dependent tumours * cautious attention to formulation science, because oral bioavailability remains a major barrier ### Evidence quality rating **2/5 — Early evidence** Mechanistic coherence is strong. Human oncology evidence is absent. ### In this section * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/anticancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/immune-effects.md) * [Shikonin Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type.md) * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/pharmacokinetics-and-metabolism.md) * [Safety & Interactions](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/safety-and-interactions.md) * [Dosing & Timing](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/dosing-and-timing.md) * [Sourcing Quality Shikonin](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sourcing-quality-shikonin.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/synergistic-combinations.md) * [Sensitisation to Conventional Therapies](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sensitisation-to-conventional-therapies.md) * [PKM2 & the Warburg Effect](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/pkm2-and-the-warburg-effect.md) * [Estrogen Receptor Mechanisms](/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonons-estrogen-receptor-mechanisms.md) ### Key references Ahmad F et al. (2024). Shikonin in breast cancer treatment: a comprehensive review of mechanisms and therapeutic potential. *Journal of Pharmacy and Pharmacology.*\ Yang J et al. (2019). ER-mediated anti-tumor effects of shikonin on breast cancer. *European Journal of Pharmacology.*\ Han X et al. (2010). A novel antiestrogen agent: shikonin inhibits estrogen-dependent cell proliferation in ERα-positive breast cancer. *Life Sciences.*\ Li Z et al. (2018). PKM2 inhibitor shikonin overcomes cisplatin resistance in bladder cancer. *PMC / PLoS ONE.*\ Lv C et al. (2021). Shikonin inhibits tumour growth of ESCC by suppressing PKM2-mediated aerobic glycolysis. *Journal of Cancer.*\ Frontiers in Pharmacology (2025). Review projecting shikonin as a therapeutic candidate in female reproductive cancers.\ Shikonin anticancer activity against lung cancer through PI3K. *ScienceDirect.*\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.